First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD®, a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD®, which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Harro Ten Wolde
Head of Global Media Relations
Phone Number: +49 (6132) 77-181352
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Nature Conservancy and Global Partners Hold Session on Improving Protected Marine Areas at UN Oceans Conference With Support From Mary Kay Inc.9.8.2022 18:33:00 CEST | Press release
The United Nations Ocean Conference 2022 took place from June 27 to July 1, in Lisbon, Portugal, and brought together more than 5,000 participants, including world leaders, entrepreneurs, youth, influencers, and scientists. The conference aimed to facilitate these stakeholders in finding science-driven innovations and solutions to respond to a multidimensional ocean crisis driven by climate change, overfishing, habitat loss, and pollution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005180/en/ The Nature Conservancy logo (Logo: The Nature Conservancy) The Nature Conservancy (TNC), with support from Mary Kay Inc., held an event in collaboration with United Nations Environment Programme (UNEP), the Government of Ecuador, the Jocotoco Foundation, the Charles Darwin Foundation for the Galapagos Islands, Re:wild, and the Marine Conservation Institute. TNC and UNEP moderated the event, highlighting the critical importance
Forescout Joins CISA’s Joint Cyber Defense Collaborative9.8.2022 18:00:00 CEST | Press release
Forescout Technologies Inc., the global leader in automated cybersecurity, today announced it has joined the Joint Cyber Defense Collaborative (JCDC) to further support the U.S. government’s focus on the cybersecurity and resilience of its industrial control systems and operational technology (ICS/OT). Established by the Cybersecurity and Infrastructure Security Agency (CISA), JCDC connects cyber defenders to enable critical thinking and planning against cyberattacks. “It’s an honor to be included in the newly expanded JCDC-ICS to share Forescout’s leadership and deep expertise in ICS/OT security,” said Tim Jones, Forescout’s US Federal Government VP of Systems Engineering. “Having worked directly with CISA for years, I know this type of collaboration between industry leaders in cybersecurity is exactly what our nation needs to protect against cyberattacks that threaten critical infrastructure systems on which our daily lives depend.” Forescout’s cybersecurity solutions are used by man
Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers9.8.2022 16:50:00 CEST | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/ Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire) Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion
TNS Targets Global Growth with Strategic Acquisition of AGNITY Global9.8.2022 16:01:00 CEST | Press release
Transaction Network Services (TNS) has today announced the acquisition of AGNITY Global, a leading provider of intelligent business communication applications and infrastructure to organizations in the telecommunications and healthcare industry verticals. The move strategically enhances TNS’ Communications Market global capabilities through AGNITY’s established channel partnerships business model that spans more than 12 countries. It will also enable TNS’ existing customers to benefit from a broader portfolio of next generation solutions. Headquartered in Silicon Valley with development and support operations in Richardson, Texas and Noida, India, AGNITY powers the networks of many global Tier-1 service providers via its scalable, carrier-grade Communication Application Server (CAS). This network agnostic, multi-service software platform offers app components and open APIs that enable service providers to address network technology transition challenges as well as future-proofing their
Evolve Additive Solutions Hires Jeff Blank as COO to Lead the Engineering and Operation Teams9.8.2022 16:00:00 CEST | Press release
Today Evolve Additive Solutions (“EAS”), a global leader in the manufacturing of capital equipment and 3D printed production AM parts, announced the appointment Jeff Blank as the company’s Chief Operating Officer. More recently Mr. Blank was the Chief Operating Officer at NanoVox / Vadient Optics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005435/en/ Jeff Blank, COO, Evolve Additive Solutions (Photo: Business Wire) As an industry veteran, Jeff has a diverse engineering and business background with a master’s in mechanical engineering from Stanford University and MBA from the University of Portland. After spending two decades delivering printers for Tektronix and Xerox Corporation, Jeff moved to 3D Systems to run their worldwide engineering and product delivery organization. Jeff specializes in scaling reliable and cost-effective products from concept to commercial success, in hardware, software, and materials. In J
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom